Acetogenic Bacteria Promoter Patents: Top Companies & Trends 2026
Acetogenic Bacteria Promoter Engineering Patents
76.7% concentration. The top 5 assignees account for 247 of the 322 records in scope — this field is claimed, not open, at the promoter-engineering layer. Annual filings rose from 17 in 2017 to a peak of 54 in 2022, then eased — read the 2025-26 tail as incomplete rather than declining. The clearest complete-year signal is the 2021-to-2024 span, where filings doubled from 9 to 18, consistent with continued investment in gas-fermentation strain engineering rather than a one-off filing wave.
- 1GENOMATICA INC90
- 2KIVERDI INC51
- 3LANZATECH NZ INC46
- 4LANZATECH INC44
- 5LANZATECH NEW ZEALAND LTD16
See the full acetogenic bacteria promoter engineering analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in acetogenic bacteria promoter engineering?
One assignee leads with 90 of the 322 records in scope, well ahead of the fifth-ranked holder at 16. The top five assignees combined account for 247 records, or 76.7% of the field, so leadership is concentrated rather than spread across many equally-sized players. Anyone assessing freedom to operate should treat that leading portfolio as the first thing to review, not one entry among many.
Is patent filing in this field still growing?
Yes, based on the last complete years of data: filings rose from 9 in 2021 to 18 in 2024, a doubling over three years, with a peak of 54 records in 2022. The 2025 and 2026 counts look lower, but publication typically lags actual filing by around 18 months, so those recent years are undercounted rather than genuinely quiet. The honest read is sustained growth through 2024 with an incomplete tail after it.
What IPC classes matter most for promoter engineering claims in acetogens?
C12P (fermentation and enzymatic synthesis) and C12N (microorganisms and genetic engineering) dominate, each covering more than 92% of the 322 records in scope. Electrolytic production methods (C25B) appear in 11.5% of records, bioreactor apparatus (C12M) in 9.9%, and peptide-related claims (C07K) in 7.1%. Because a single record can carry several class tags, these percentages add up to well over 100% and should not be read as market share splits.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Acetogenic Bacteria Promoter Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.